RESEARCH ARTICLE


New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide



Jan M. Keppel Hesselink*
Institute for Neuropathic Pain,Bosch en Duin, the Netherlands.


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 195
Abstract HTML Views: 1280
PDF Downloads: 317
Total Views/Downloads: 1792
Unique Statistics:

Full-Text HTML Views: 119
Abstract HTML Views: 813
PDF Downloads: 259
Total Views/Downloads: 1191



© 2012 Jan M. Keppel Hesselink et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* correspondence to this author at the Institute for Neuropathic Pain, Bosch en Duin, the Netherlands; Tel: 0031-6-51700527; E-mail: jan@neuropathie.nu; info@ores.nl


Abstract

Persistent pain in neuropathic conditions is often quite refractory to conventional analgesic therapy, with most patients obtaining, at best, only partial relief of symptoms. The tendency still exists to treat these complex pains with one or a combination of two analgesics at the most. Given the complex nature of the underlying pathogenesis, this approach more often than not fails to produce a meaningful improvement. New targets are therefore badly needed. In this regard non-neuronal cells – glia and mast cells in particular - are emerging as new targets for the treatment of neuropathic pain. An extensive preclinical database exists showing that the naturally occurring fatty acid amide palmitoylethanolamide is endowed with anti-inflammatory activity, and clinical trials assessing the efficacy and safety of palmitoylethanolamide in neuropathic pain have been successful in generating proof-of-concept for treatment in man. Here I will review salient preclinical and clinical evidence supporting non-neuronal cells as viable targets in the treatment of neuropathic pain. This will be followed by a discussion of recent proof-of-concept clinical trials demonstrating the efficacy and safety of palmitoylethanolamide in the treatment of various neuropathic pain states.

Keywords: New Targets, Pain, Non-Neuronal Cells, Palmitoylethanolamide.